Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
397
mi
from 43215
Allentown, PA
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
397
mi
from 43215
Allentown, PA
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
344
mi
from 43215
Danville, PA
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Geisinger Medical Center
344
mi
from 43215
Danville, PA
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
277
mi
from 43215
State College, PA
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Geisinger Medical Group
277
mi
from 43215
State College, PA
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
385
mi
from 43215
Wilkes-Barre, PA
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
385
mi
from 43215
Wilkes-Barre, PA
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
747
mi
from 43215
Sioux Falls, SD
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Avera McKennan Hospital and University Health Center
747
mi
from 43215
Sioux Falls, SD
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
747
mi
from 43215
Sioux Falls, SD
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Medical X-Ray Center, P. C.
747
mi
from 43215
Sioux Falls, SD
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
1160
mi
from 43215
Sioux Falls, SD
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Sioux Valley Hospital at University of South Dakota Medical Center
1160
mi
from 43215
Sioux Falls, SD
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
498
mi
from 43215
La Crosse, WI
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Franciscan Skemp Healthcare
498
mi
from 43215
La Crosse, WI
Click here to add this to my saved trials
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated:  7/9/2015
1268
mi
from 43215
Regina,
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age
Status: Enrolling
Updated: 7/9/2015
Allan Blair Cancer Centre at Pasqua Hospital
1268
mi
from 43215
Regina,
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
1645
mi
from 43215
Scottsdale, AZ
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mayo Clinic Scottsdale
1645
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
673
mi
from 43215
Jacksonville, FL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
299
mi
from 43215
Aurora, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Rush-Copley Cancer Care Center
299
mi
from 43215
Aurora, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
316
mi
from 43215
Bloomington, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Joseph Medical Center
316
mi
from 43215
Bloomington, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
371
mi
from 43215
Canton, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Graham Hospital
371
mi
from 43215
Canton, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
428
mi
from 43215
Carthage, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Memorial Hospital
428
mi
from 43215
Carthage, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
333
mi
from 43215
Eureka, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Eureka Community Hospital
333
mi
from 43215
Eureka, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
391
mi
from 43215
Galesburg, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Galesburg Clinic, PC
391
mi
from 43215
Galesburg, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
391
mi
from 43215
Galesburg, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Galesburg Cottage Hospital
391
mi
from 43215
Galesburg, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
371
mi
from 43215
Havana, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mason District Hospital
371
mi
from 43215
Havana, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
339
mi
from 43215
Hopedale, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Hopedale Medical Complex
339
mi
from 43215
Hopedale, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
288
mi
from 43215
Joliet, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Joliet Oncology-Hematology Associates, Limited - West
288
mi
from 43215
Joliet, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
370
mi
from 43215
Kewanee, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Kewanee Hospital
370
mi
from 43215
Kewanee, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
404
mi
from 43215
Macomb, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
McDonough District Hospital
404
mi
from 43215
Macomb, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
316
mi
from 43215
Normal, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
BroMenn Regional Medical Center
316
mi
from 43215
Normal, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
316
mi
from 43215
Normal, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Community Cancer Center
316
mi
from 43215
Normal, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
319
mi
from 43215
Ottawa, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
OSF Saint Elizabeth Medical Center
319
mi
from 43215
Ottawa, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
319
mi
from 43215
Ottawa, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
319
mi
from 43215
Ottawa, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
350
mi
from 43215
Pekin, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Cancer Treatment Center at Pekin Hospital
350
mi
from 43215
Pekin, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
350
mi
from 43215
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Proctor Hospital
350
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
352
mi
from 43215
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
CCOP - Illinois Oncology Research Association
352
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
349
mi
from 43215
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
349
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
349
mi
from 43215
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Methodist Medical Center of Illinois
349
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
349
mi
from 43215
Peoria, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
OSF St. Francis Medical Center
349
mi
from 43215
Peoria, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
333
mi
from 43215
Peru, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Illinois Valley Community Hospital
333
mi
from 43215
Peru, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
337
mi
from 43215
Spring Valley, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Margaret's Hospital
337
mi
from 43215
Spring Valley, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
274
mi
from 43215
Urbana, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Carle Cancer Center at Carle Foundation Hospital
274
mi
from 43215
Urbana, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
274
mi
from 43215
Urbana, IL
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
CCOP - Carle Cancer Center
274
mi
from 43215
Urbana, IL
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
163
mi
from 43215
Beech Grove, IN
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Francis Hospital and Health Centers - Beech Grove Campus
163
mi
from 43215
Beech Grove, IN
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
234
mi
from 43215
Michigan City, IN
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Saint Anthony Memorial Health Centers
234
mi
from 43215
Michigan City, IN
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
99
mi
from 43215
Richmond, IN
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Reid Hospital & Health Care Services, Incorporated
99
mi
from 43215
Richmond, IN
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
569
mi
from 43215
Ames, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
McFarland Clinic, PC
569
mi
from 43215
Ames, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
471
mi
from 43215
Cedar Rapids, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
St. Luke's Hospital
471
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
469
mi
from 43215
Cedar Rapids, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Cedar Rapids Oncology Associates
469
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
469
mi
from 43215
Cedar Rapids, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mercy Regional Cancer Center at Mercy Medical Center
469
mi
from 43215
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
563
mi
from 43215
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mercy Capitol Hospital
563
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
565
mi
from 43215
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
CCOP - Iowa Oncology Research Association
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
565
mi
from 43215
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
565
mi
from 43215
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
566
mi
from 43215
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Medical Oncology and Hematology Associates at Mercy Cancer Center
566
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated:  7/9/2015
566
mi
from 43215
Des Moines, IA
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer
Status: Enrolling
Updated: 7/9/2015
Mercy Cancer Center at Mercy Medical Center - Des Moines
566
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials